EOLS - Evolus, Inc.
NEXT EARNINGS:
Mar 3, 2026
(in 6 days)
EPS Est: $0.06
|
Rev Est: $89.6M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$15.00
DETAILS
HIGH:
$17.00
LOW:
$13.00
MEDIAN:
$15.00
CONSENSUS:
$15.00
UPSIDE:
248.84%
Market Cap:
278.73M
Volume:
427,884
Avg Volume:
1,142,493
52 Week Range:
4.091-14.94
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Beta:
1.01
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
372
IPO Date:
2018-02-08
EPS (TTM):
-0.81
P/E Ratio:
-13.58
Revenue (TTM):
266.27M
Total Assets:
232.57M
Total Debt:
129.98M
Cash & Equiv:
86.95M
Rev Growth (5Y):
50.1%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-18.3%
Debt/Equity:
23.54
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $-0.14 | $-0.19 | +26.3% | $69.0M | $89.6M | -23.0% |
| 2025-08-05 | $-0.24 | $-0.09 | -166.7% | $69.4M | $85.3M | -18.7% |
| 2025-05-07 | $-0.18 | $-0.10 | -80.0% | $68.1M | $82.3M | -17.3% |
| 2025-03-04 | $0.01 | $0.02 | -50.0% | $78.9M | $71.8M | +10.0% |
| 2024-11-06 | $-0.19 | $-0.08 | -137.5% | $61.1M | $77.0M | -20.7% |
| 2024-07-31 | $-0.07 | $-0.06 | -23.1% | $66.9M | $63.1M | +6.1% |
| 2024-05-07 | $-0.13 | $-0.07 | -85.7% | $59.3M | $57.3M | +3.5% |
| 2024-03-07 | $-0.14 | $-0.07 | -100.0% | $61.0M | $60.1M | +1.6% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 266.27M | 202.09M | 148.62M | 99.67M | 56.54M | 34.92M | 0 | 0 | 0 | 0 |
| Net Income | (50.42M) | (61.69M) | (74.41M) | (46.81M) | (163.01M) | (90.03M) | (46.87M) | (4.48M) | (20.07M) | (31.11M) |
| EPS | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | -0.19 | -1.08 | -1.67 |
| Total Assets | 232.57M | 189.00M | 177.98M | 257.48M | 209.07M | 240.44M | 171.84M | 152.23M | 77.50M | 81.30M |
| Total Debt | 129.98M | 126.55M | 74.42M | 74.74M | 138.32M | 96.55M | 16.90M | 211.33M | 59.76M | 46.17M |
| Cash & Equivalents | 86.95M | 62.84M | 53.92M | 146.26M | 102.56M | 109.89M | 93.16M | 0 | 0 | 4.00M |
| Operating Cash Flow | (18.00M) | (34.01M) | (84.91M) | (33.39M) | (57.87M) | (93.38M) | (25.67M) | (13.04M) | (13.27M) | (36.38M) |
| Free Cash Flow | (19.47M) | (35.63M) | (87.85M) | (34.36M) | (61.01M) | (97.95M) | (25.68M) | (13.04M) | (13.27M) | (36.38M) |
| FCF per Share | -0.31 | -0.63 | -1.57 | -0.69 | -1.81 | -3.47 | -1.05 | -0.55 | -0.71 | -1.96 |
| Book Value | 5.52M | (20.69M) | 18.50M | 81.88M | (72.96M) | 79.46M | (123.03M) | (75.54M) | (7.11M) | 12.00M |
| Cash & ST Investments | 86.95M | 62.84M | 53.92M | 146.26M | 107.56M | 129.80M | 93.16M | 0 | 0 | 4.00M |
| ROC Equity | -9.13 | N/A | -4.02 | -0.57 | N/A | -1.13 | N/A | N/A | N/A | -2.59 |